This author's PDF version corresponds to the article as it

appeared upon acceptance. Fully formatted PDF versions will be

made available soon.

Economic value of nutritional support methods in gastrointestinal

cancer: a quantitative meta-analysis

doi: 10.6133/apjcn.202003/PP.0002 Published online: March 2020

Running title: Nutritional support in gastrointestinal cancer treatment

Mingwei Zhu MD¹, Wei Chen MD², Hua Jiang MD³, Sainan Zhu MS⁴, Jingyong Xu MD¹, Wenlei Bao MM⁵, Yan Dang MM⁵, Michael Yao-Hsien Wang MM⁶

¹Department of General Surgery, Beijing Hospital, National Geriatrics Center, Beijing, China ²Department of Clinical Nutrition, Department of Health Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China ³Institute for Emergency and Disaster Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

⁴Department of Biostatistics, Peking University First Hospital, Beijing, China

⁵Medical Affairs, Abbott Nutrition, Shanghai, China

⁶Medical Affairs, Abbott Nutrition, Taipei, Taiwan

Authors' email addresses and contributions:

Mingwei Zhu, Wei Chen, Wenlei Bao and Yan Dang conceived and designed research; Hua Jiang, Sainan Zhu, Jingyong Xu collected data and conducted the data analysis; Mingwei Zhu, Wei Chen, Jingyong Xu and Michael Yao-Hsien Wang interpreted data; Wenlei Bao and Yan Dang wrote the initial paper; Mingwei Zhu, Hua Jiang and Michael Yao-Hsien Wang revised the paper; Mingwei Zhu had primary responsibility for final content. All authors read and approved the final manuscript

Corresponding Author: Dr Mingwei Zhu, Department of General Surgery, Beijing Hospital, No.1 Dahua Road, Beijing 110100, China. Tel: +8613801011304. Fax: +86-010-65132969. Email: zhumw2013@163.com

ABSTRACT

Background and Objectives: Multiple studies of the relative economic value of different nutritional support methods for patients with gastrointestinal cancer have provided inconsistent results. Methods and Study Design: The PUBMED and EMBASE databases were systematically searched through September 30, 2018to identify latent studies of the benefits of parenteral nutrition (PN), enteral nutrition (EN) or conventional intervention (CI) in gastrointestinal cancer patients. A fixed-effects model or random-effects model was applied depending on the heterogeneity of the studies. Statistical analysis was conducted using R software. A total of 728 studies were reviewed, and 21 studies published from 1998 to 2018 were included in the final analysis. Results: The results showed that the hospitalization expenditure of the EN group was 3938 RMB less than that of the PN group. Similarly, the EN group had a shorter length of hospitalization than the PN and CI groups. The infection rate was lower in the EN group (12%) than in the PN group (16%) and CI group (20%). Subgroup analysis showed that gastrointestinal cancer patients who received oral nutritional supplements had the lowest infection rate (11%) after surgery. Conclusions: EN, especially oral nutritional supplements, has a positive economic impact on patients with gastrointestinal cancer, based on reductions in the post-operative infection rate, length of hospitalization, and hospitalization expenditure.

Key Words: nutritional support, economic value, parenteral nutrition, enteral nutrition, meta-analysis

INTRODUCTION

The Global Cancer Statistics 2018 reported that over 1.8 million new colorectal cancer cases and 1,000,000 new stomach cancer cases were estimated to occur in 2018, while the mortality rates for these cancers were also ranked in the top three of all cancers.¹ For all gastric cancer patients with surgical indications, surgical treatment is still the first-line treatment. The operation for gastric cancer itself involves a large area of trauma, requiring reconstruction of the digestive tract and a long fasting time after surgery.² Furthermore, patients with malignant tumors undergoing selective gastrointestinal surgery have a high risk of post-operative infection, such as wound infection and respiratory tract infection.³ These factors not only bring uncertainty regarding the clinical response, but also prolong hospital stays and place additional financial burden on patients. Studies have confirmed that nutritional deficiency will lead to a decrease in the quality of life of patients, an increase in treatment-related adverse

reactions, and a decrease in the treatment response rate and survival rate.^{4,5} Malnutrition is one indicator of severe illness and poor prognosis.⁶

Therefore, adequate nutritional support is of great significance for the recovery of gastrointestinal cancer patients after surgical treatment. Nutritional support for patients who have undergone surgery for gastrointestinal tumor removal generally involves parenteral nutrition (PN) or enteral nutrition (EN). PN usually achieves a positive nitrogen balance and reduces weight loss, but it may lead to inflammation.⁷ Although it has been demonstrated that PN alone is superior to non-nutritional support or conventional intervention (CI),⁸ EN, especially with oral nutritional supplements (ONS), has been increasingly valued by clinicians in recent years due the advantages of conforming to physiological conditions and contributing to the recovery of gastrointestinal function and morphology.⁹

However, studies evaluating the effectiveness of nutritional support for patients with gastrointestinal cancer have mostly focused on clinical indicators in recent years, while economic evaluation of different nutritional support modes has been neglected, especially a quantitative comparison among different types of nutritional interventions. Therefore, the present study reviewed and quantified economic factors associated with different types of nutritional interventions in patients with gastrointestinal cancer.

MATERIALS AND METHODS

Search strategy

A systematic review and meta-analysis were conducted in accordance with the Systematic Review and Meta-analysis (PRISMA). The Pubmed and Embase databases were searched for qualifying research from the establishment of each database through September 30, 2108 by applying the following search terms:

Pubmed:

((((((((((((((cost[Title/Abstract]) OR effectiveness[Title/Abstract]) OR effective[Title/Abstract]) OR effect[Title/Abstract]) OR efficacy[Title/Abstract]) OR economic[Title/Abstract]) OR expense[Title/Abstract]) OR budget[Title/Abstract]) OR price[Title/Abstract]) OR benefit[Title/Abstract]) OR finance[Title/Abstract])) AND ((((((Nutritional Support[Title/Abstract]) OR Enteral Nutrition[Title/Abstract]) OR Parenteral Nutrition[Title/Abstract]) OR Oral Nutrition[Title/Abstract])) AND (((((Gastrointestinal cancer[Title/Abstract]) Neoplasms[MeSH] Terms]) OR stomach OR Colorectal cancer[Title/Abstract]) OR gastric cancer[Title/Abstract]) OR Colon cancer [Title/Abstract]). Embase:

#1.'gastrointestinal neoplasms':ab,ti OR 'stomach cancer':ab,ti OR 'colorectal cancer':ab,ti OR 'gastric cancer':ab,ti OR 'colon cancer':ab,ti

#2.'nutritional support':ab,ti OR 'enteral nutrition':ab,ti OR 'parenteral nutrition':ab,ti OR 'oral nutrition':ab,ti

#3. 'cost':ab,ti OR 'effective':ab,ti OR 'effectiveness':ab,ti OR 'effect':ab,ti OR 'efficacy':ab,tiOR 'economic':ab,ti OR 'expense':ab,ti OR 'budget':ab,ti OR 'price':ab,ti OR 'benefit':ab,ti OR 'finance':ab,ti

#4. #1 and #2 and #3

When we review the Embase, the duplicate databases were removed, in order to reduce the repetition rate. The studies were restricted to the ones which final publications are in English. Study selection began with a review of titles and abstracts, but if the information obtained was insufficient to support the decision, the full text needed to be read. In order to collect as many studies as possible, studies were also identified from citations of other papers and references. All searches were conducted by two independent investigators, and any conflict was resolved through discussion.

Inclusion and exclusion criteria

The eligibility criteria for inclusion of studies in the present analysis were as follows: 1) Patients were pathologically diagnosed with gastrointestinal cancer (limited to gastric and colorectal position); 2) The study compared clinical outcomes between patients who received PN and EN or CI; 3) The patients underwent surgical treatment; and 4) High-quality data could be extracted from the study.

Studies that did not meet the above inclusion criteria were excluded.

Data extraction

The data extraction process was completed by two researchers, with judgement by the third researcher when unclear information was encountered. The main data extracted for the present study were: article title, author, publication time, country, number of subjects, patients' nutritional status, location of disease, nutritional support administered, type of study (e.g., randomized controlled trial [RCT]), use of ONS intervention, hospitalization expenditure (the total cost of the hospitalization, including surgery, nutrition intervention and the treatment of all complications), infection rate (all infection complications, including surgical site infections, sepsis, pneumonia, UTI, and others infections) and other outcome indicators.

In this study, RMB was applied as the currency for comparisons and analyses. When costs in other currencies were given in the studies, we converted them according to the average exchange rate of the year in which the study was conducted.

Statistical analysis

The R software package was used for data analysis in this study, and p<0.05 was considered statistically significant. For continuous data, mean and standard deviation (SD) were applied with the 95% confidence intervals (95% CI). Count data were presented as rates. Heterogeneity was estimated using the Q-test and I². If I²>50%, the studies were considered to have homogeneity, and the fixed-effects model was used for analysis. Otherwise, the random-effects model was applied for analysis. In addition, sensitivity analysis was conducted if needed.

RESULTS

Eligible studies

A total of 728 studies were reviewed, and 142 studies were removed due to duplication. Another 500 studies were excluded due to irrelevance to the topic based on a review of the titles and abstracts. The full text of 84 potential studies was read, and of these, 21 met our inclusion criteria for final analysis.^{8,10-29} The detailed search steps are presented in the flow diagram in Figure 1.

Basic information of included studies

The basic details of the 21 included studies, which were published from 1998 to 2018, are presented in Table 1. Although most of the research was conducted in Asia, some European studies were included in the analysis. The location of cancer in patients was limited to gastrointestinal cancer (6 studies), gastric cancer (7 studies) and colorectal cancer (8 studies). In terms of nutritional support interventions, EN was applied in 20 studies, PN in 12 studies, and CI in 6 studies. Only 3 of the 21 studies were designed as non-RCTs.

Comparison of hospitalization expenditure

Hospitalization expenditure was compared between EN and PN groups from three studies. The heterogeneity between the two groups was $I^2=86\%$, with p<0.01. Therefore, a random effects model was used to analyze the heterogeneity. The hospitalization expenditure of the EN group was 3938 RMB less (95% CI -6999, -796) than that in the PN group (Figure 2).

Similarly, Figure 3 shows that the cost of hospitalization in the EN group was 3494 RMB less than that in the CI group (95% CI -5871, -1117).

Comparison of length of hospitalization (LOH)

A total of 10 studies were included in the comparative analysis of LOH between EN and PN groups. The heterogeneity between groups was $I^2=82\%$, and the random effects model was used for the analysis. The results showed that the LOH in EN group was 3.09 days (95% CI - 3.98, -2.20) shorter than that in the PN group (Figure 4).

Another 10 studies were analyzed to explore the difference in LOH between EN and CI groups. Figure 5 shows that patients in the CI group were hospitalized for 2.64 days longer than those in EN group. Further subgroup analysis provided consistent results; the LOH of patients who received ONS intervention in the EN group was 2.57 days less than that of patients in the CI group and 2.72 days less than that in the CI group (Figure 5).

Comparison of postoperative infection rates

Infection rate in the EN group

Fourteen studies were included in the analysis (Figure 6). The heterogeneity between groups was $I^2=76\%$, and the results of the random effects model showed that the infection rate of the EN group was 12% (95% CI 0.08, 0.19). At the same time, subgroup analysis showed that the infection rate with ONS was 11% (heterogeneity $I^2=5\%$, fixed effect model was applied), and the infection rate was 13% with other interventions in the EN group.

Infection rate in the PN group

A total of nine studies were included in the analysis. The heterogeneity between groups was $I^2=83\%$, with p<0.01. Therefore, a random effects model was used for analysis. Analysis showed that the postoperative infection rate in the PN group was 16% (95% CI 0.09, 0.26; Figure 7).

Infection rate in the CI group

Data from a total of six studies were included in the random effects model to analyze the postoperative infection rate in the CI group. Figure 8 shows that the postoperative infection rate in the CI group was 20% (95% CI 0.13, 0.30).

Sensitivity analysis

Based on the stability of the results, a sensitivity analysis was conducted. The results indicated that a study should be deleted from the analysis of comparative hospitalization expenditure between EN and PN groups, due to obvious data distortion. With removal of that study, the difference in the hospitalization expenditure was reduced from 3938 RMB to 1717 RMB between the two groups. Therefore, the study conducted by Niu et al (2015) was deleted from the comparison of hospitalization expenditures between EN and PN groups.

In order to collect as much data as possible, three non-RCT studies were included in the present study. After the sensitivity analysis, the three papers had little influence on the comparisons among the groups. Therefore, the three papers passed the sensitivity analysis.

DISCUSSION

The causes and development of malnutrition in cancer patients is very diverse. A common view is that abnormal metabolism of the tumor leads to malnutrition of patients who suffer from cancer. Tumor cells rapidly proliferate and divide, consuming much glucose, fat and amino acids in patients, and the body's reaction to tumors involves the production of many cytokines such as tumor necrosis factor, interleukin, interferon and prostaglandins,³⁰ which not only cause a series of metabolic disorders but also play important roles in malnutrition and the production of dyscrasia. Therefore, there is a close relationship between malnutrition, disease and complications.³¹

The poor nutritional status of cancer patients can affect clinical outcomes to some extent, and it will also bring greater economic burden to patients and reduce the efficiency of allocation of medical resources. A Korean study reported that low quality of life and nutritional status are associated with an increased economic burden from cancer treatment.³² Furthermore, Kernick proposed that combining the output of health intervention resources with the input resources is very important for clinical decision-making, and researchers should provide different interventions as multiple options for clinical decision makers.³³

At present, the main methods of nutritional intervention for patients with gastrointestinal cancer undergoing surgery are EN and PN. EN is a nutritional support method that provides a metabolic nutrient matrix and other nutrients via oral or tube feeding into the gastrointestinal tract. PN support provides nutrients (including amino acids, fats, carbohydrates, vitamins and minerals) to inhibit catabolism, promote anabolism and maintain the function of structural proteins for patients who are unable to absorb nutrients through the gastrointestinal tract or who cannot meet their own metabolic needs.

In recent years, some studies have shown that although PN costs more than EN, most patients prefer PN, especially elderly patients.^{34,35} Similarly, our study also found that the EN group had lower hospitalization costs than the PN group, which may be due to the economics of EN itself. However, lower intra-group infection rates and shorter LOH may also influence the cost of hospitalization.

From the perspective of the LOH, the EN group had a shorter LOH than the PN and CI groups. Timely administration of EN and the lower infection rate are factors that affect the LOH. However, it is worth noting that patients who generally use EN may have better physical status, which could also have some influence. However, the present study is mostly based on RCTs, so the impact in this area may not be significant.

PN treatment is convenient and can provide a high-quality nitrogen source and calories in a short time, which is well-tolerated by patients. Because it is easily absorbed and can quickly and effectively improve the nutritional status of patients, PN support is more appropriate for patients with dietary disorders and impaired digestive tract function. However, PN is prone to complications, with the most common complication being catheter-related infection. Moreover, the intestinal mucosa atrophies due to the long-term idleness of the intestinal tract, resulting in impaired intestinal mucosal immune barrier function and increased intestinal mucosal permeability, which is likely to promote intestinal infection. In our study, the infection rate in the PN group was 16%, which was higher than that in the EN group (12%). However, the infection rate was highest in the CI group, which means the nutritional interventions were beneficial for the prevention of complications during recovery from surgery for gastrointestinal cancer.

ONS, a type of EN support, showed a more meaningful impact in this study. Compared to other types of EN support, ONS resulted in the lowest infection rate (11%) due to the benefits of its non-invasive nutritional support. Unfortunately though, in terms of LOH and hospitalization costs, the data in the literature included in this study were insufficient to permit comparison of other aspects according to use of ONS. We did find that support with ONS can positively impact the LOH, compared with CI.

As other quantitative research studies, this study has some limitations. First, too few countries and regions are represented. However, in order to ensure the quality of the included studies, we balanced the research results from various regions as much as possible. Second, although this study was an economic evaluation study, we performed a meta-analysis to analyze the impact of different nutritional support methods in gastrointestinal cancer patients.

Due to the inaccessibility of data, we included three non-RCT studies. These three articles were retained though after sensitivity analysis.

Conclusion

The results of the present study suggest that EN, as a form of nutritional support, has a positive impact on gastrointestinal cancer patients after surgical treatment, including a lower post-operative infection rate, shorter LOH and lower hospitalization expenditure. Although there is still controversy regarding the use of nutritional support treatment in patients with malignant tumors,^{36,37} EN, especially ONS, can generate a positive economic impact for patients with gastrointestinal cancer.

CONFLICT OF INTEREST AND FUNDING DISCLOSURE

Mingwei Zhu, Wei Chen, Hua Jiang, Sainan Zhu and Jingyong Xu were involved in the conduct of the study as investigators. Wenlei Bao, Yan Dang, Michael Yao-Hsien Wang are employees of Abbott Nutrition. The information presented in this article is based on clinical evidence and is not affected by any financial relationship. No additional known conflicts of interests exist and no honoraria were offered or received in the writing of the present report.

Financial support for the publication was provided by Abbott Nutrition, China.

REFERENCES

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424. doi: 10.3322/caac.21492.
- Martin CM, Doig GS, Heyland DK, Morrison T, Sibbald WJ. Multicentre, cluster-randomized clinical trial of algorithms for critical-care enteral and parenteral therapy (ACCEPT). CMAJ. 2004;170:197-204.
- Marano L, Porfidia R, Pezzella M, Grassia M, Petrillo M, Esposito G et al. Clinical and immunological impact of early postoperative enteral immunonutrition after total gastrectomy in gastric cancer patients: a prospective randomized study. Ann Surg Oncol. 2013;20:3912-8. doi: 10.1245/s10434-013-3088-1.
- 4. Rosa F, Bossola M, Pacelli F, Alfieri S, Doglietto GB. Malnutrition and postoperative complications in abdominal surgery. Ann Surg. 2011;254:666; author reply -7. doi: 10.1097/SLA.0b013e3182306457
- 5. Bozzetti F, Forbes A. The ESPEN clinical practice Guidelines on Parenteral Nutrition: present status and perspectives for future research. Clin Nutr. 2009;28:359-64. doi: 10.1016/j.clnu.2009.05.010.
- 6. Arends J, Bodoky G, Bozzetti F, Fearon K, Muscaritoli M, Selga et al. ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clin Nutr. 2006;25:245-59. doi: 10.1016/j.clnu.2006.01.020.

- Freitas R, Nogueira RJN, Cozzolino SMF, Vasques ACJ, Hessel G. Influence of selenium supplementation on patients with inflammation: A pilot double blind randomized study. Nutrition. 2017;41:32-6. doi: 10.1016/j.nut.2017.03.007.
- Wu GH, Zhang YW, Pan HT, Zhang B, Liu ZH, Wu ZH. A randomized controlled trial of postoperative artificial nutrition in malnourished patients with gastrointestinal cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 2007;10:546-9.
- 9. Chen ZH, Lin SY, Dai QB, Hua J, Chen SQ. The effects of pre-operative enteral nutrition from nasal feeding tubes on gastric outlet obstruction. Nutrients. 2017;9. doi: 10.3390/nu9040373.
- Chen W, Zhang Z, Xiong M, Meng X, Dai F, Fang J, Wan H, Wang M. Early enteral nutrition after total gastrectomy for gastric cancer. Asia Pac J Clin Nutr. 2014;23:607-11. doi: 10.6133/apjcn.2014.23.4.15.
- Chen Y, Liu BL, Shang B, Chen AS, Liu SQ, Sun W, Yin HZ, Yin JQ, Su Q. Nutrition support in surgical patients with colorectal cancer. World J Gastroenterol. 2011;17:1779-86. doi: 10.3748/wjg.v17.i13.1779.
- Gianotti L, Braga M, Nespoli L, Radaelli G, Beneduce A, Di Carlo V. A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer. Gastroenterology. 2002;122:1763-70. doi: 10.1053/gast.2002.33587.
- Gianotti L, Braga M, Vignali A, Balzano G, Zerbi A, Bisagni P, Di Carlo V. Effect of route of delivery and formulation of postoperative nutritional support in patients undergoing major operations for malignant neoplasms. Arch Surg. 1997;132:1222-9; discussion 9-30. doi: 10.1001/archsurg.1997.01430350072012.
- Gunerhan Y, Koksal N, Sahin UY, Uzun MA, Eksioglu-Demiralp E. Effect of preoperative immunonutrition and other nutrition models on cellular immune parameters. World J Gastroenterol. 2009;15:467-72. doi: 10.3748/wjg.15.467.
- Kamei H, Hachisuka T, Nakao M, Takagi K. Quick recovery of serum diamine oxidase activity in patients undergoing total gastrectomy by oral enteral nutrition. Am J Surg. 2005;189:38-43. doi: 10.1016/j.amjsurg.2004.03.015.
- 16. Kim HU, Chung JB, Kim CB. The comparison between early enteral nutrition and total parenteral nutrition after total gastreetomy in patients with gastric cancer: the randomized prospective study. Korean J Gastroenterol. 2012;59:407-13. doi: 10.4166/kjg.2012.59.6.407.
- Klek S, Kulig J, Sierzega M, Szybinski P, Szczepanek K, Kubisz A, Kowalczyk T, Gach T, Pach R, Szczepanik AM. The impact of immunostimulating nutrition on infectious complications after upper gastrointestinal surgery: a prospective, randomized, clinical trial. Ann Surg. 2008;248:212-20. doi: 10.1097/SLA.0b013e318180a3c1.
- Klek S, Sierzega M, Szybinski P, Szczepanek K, Scislo L, Walewska E, Kulig J. Perioperative nutrition in malnourished surgical cancer patients - a prospective, randomized, controlled clinical trial. Clin Nutr. 2011;30:708-13. doi: 10.1016/j.clnu.2011.07.007.

- Li B, Liu HY, Guo SH, Sun P, Gong FM, Jia BQ. Impact of early enteral and parenteral nutrition on prealbumin and high-sensitivity C-reactive protein after gastric surgery. Genet Mol Res. 2015;14:7130-5. doi: 10.4238/2015.June.29.6.
- 20. Li B, Liu HY, Guo SH, Sun P, Gong FM, Jia BQ. The postoperative clinical outcomes and safety of early enteral nutrition in operated gastric cancer patients. J buon. 2015;20:468-72.
- 21. Manasek V, Bezdek K, Foltys A, Klos K, Smitka J, Smehlik D. The impact of high protein nutritional support on clinical outcomes and treatment costs of patients with colorectal cancer. Klin Onkol. 2016;29:351-7.
- 22. Mi L, Zhong B, Zhang DL, Zhou YB, Wang DS. Effect of early oral enteral nutrition on clinical outcomes after gastric cancer surgery. Zhonghua Wei Chang Wai Ke Za Zhi. 2012;15:464-7.
- 23. Bardram L, Funch Jensen PM, Herlufsen P, Mogensen TS, Kehlet H. Laparoscopic excision of the rectum. An advanced technique or true clinical progress? Ugeskr Laeger. 1996;158:5911-4.
- 24. Wang D, Zhong B, Zhao P, Liu X, Zhou Y. A randomized control study of early oral enteral nutrition after colorectal cancer operation. Zhonghua Wei Chang Wai Ke Za Zhi. 2014;17:977-80.
- 25. Wang J, Zhao J, Zhang Y, Liu C. Early enteral nutrition and total parenteral nutrition on the nutritional status and blood glucose in patients with gastric cancer complicated with diabetes mellitus after radical gastrectomy. Exp Ther Med. 2018;16:321-7. doi: 10.3892/etm.2018.6168.
- 26. Wang ZH, Zhong B, Xiang JY, Zhou YB, Wang DS. Effect of early oral enteral nutrition on clinical outcomes after colorectal cancer surgery. Zhonghua Wei Chang Wai Ke Za Zhi. 2013;16:735-8.
- 27. Yang DJ, He WL, Wang L, Xu JB, Peng JJ, Wu H, Song W, Zhang CH, He YL. Effect of postoperative early enteral nutrition on the recovery of humoral immune function in patients with colorectal carcinoma undergoing elective resection. Zhonghua Wei Chang Wai Ke Za Zhi. 2013;16:1051-4.
- 28. Zhang YX, Liu HY, Li YP, Wang WY. Effect of early enteral nutrition on postoperative recovery in patients with colon cancer. Cancer Research and Clinic. 2014;26:470-2.
- 29. Yu HZ, Long X, Liu CM, Cao YL, Li SX, Wu XQ. Impact of enteral nutrition or parenteral nutrition in post-operative colorectal cancer patients on viscera organ functions and "passing wind" time. Chinese Journal of Clinical Nutrition. 2009;17:268-70.
- 30. Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol. 2014;26:54-74. doi: 10.1016/j.smim.2014.01.001.
- 31. Lidder P, Flanagan D, Fleming S, Russell M, Morgan N, Wheatley T, Rahamin J, Shaw S, Lewis S. Combining enteral with parenteral nutrition to improve postoperative glucose control. Br J Nutr. 2010;103:1635-41. doi: 10.1017/s0007114509993631.
- 32. Ahn S, Jung H, Kim S, Shin SJ, Park CG, Chu SH. Quality of life among Korean gastrointestinal cancer survivors. Eur J Oncol Nurs. 2017;30:15-21. doi: 10.1016/j.ejon.2017.07.002.
- 33. Kernick DP. Has health economics lost its way? Bmj. 1998;317:197-9. doi: 10.1136/bmj.317.7152.197.
- Scolapio JS, Picco MF, Tarrosa VB. Enteral versus parenteral nutrition: the patient's preference. JPEN J Parenter Enteral Nutr. 2002;26:248-50. doi: 10.1177/0148607102026004248.

- 35. Seike J, Tangoku A, Yuasa Y, Okitsu H, Kawakami Y, Sumitomo M. The effect of nutritional support on the immune function in the acute postoperative period after esophageal cancer surgery: total parenteral nutrition versus enteral nutrition. J Med Invest. 2011;58:75-80. doi: 10.2152/jmi.58.75.
- 36. Hill A, Kiss N, Hodgson B, Crowe TC, Walsh AD. Associations between nutritional status, weight loss, radiotherapy treatment toxicity and treatment outcomes in gastrointestinal cancer patients. Clin Nutr. 2011;30:92-8. doi: 10.1016/j.clnu.2010.07.015.
- 37. Halpern-Silveira D, Susin LR, Borges LR, Paiva SI, Assuncao MC, Gonzalez MC. Body weight and fat-free mass changes in a cohort of patients receiving chemotherapy. Support Care Cancer. 2010;18:617-25. doi: 10.1007/s00520-009-0703-6.

| Title | Authors | Publication | Country | | of case | | Nutrition | Intervention | | | Location of | Treatment | ONS | RCT |
|--|----------------|-------------|---------|-----|---------|-----|------------------|--|---|-------------------------------------|-----------------------------|-----------|--------------|-----|
| | Autions | year | | EN | PN | CI* | status | EN | PN | CI* | cancer | | | |
| A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer | Gianotti, L | 2002 | Italy | 102 | | 102 | Weight loss <10% | Standard enteral nutrition (preoperative+ postoperative) | | Conventional postoperative care | | Surgery | YES | RCT |
| Early enteral nutrition and total parenteral nutrition on the nutritional status and blood glucose in patients with gastric cancer complicated with diabetes mellitus after radical gastrectomy | Wang, J | 2018 | China | 66 | 63 | | Not given | Early enteral nutrition (postoperative) | Total parenteral nutrition (postoperative) | | Gastric cancer | Surgery | NO | RCT |
| Effect of preoperative immunonutrition and other nutrition models on cellular immune parameters | Gunerhan, Y | , 2009 | Turkey | 13 | | 13 | Not given | Standard enteral nutrition (preoperative) | | Normal feeding (preoperative) | Gastrointes tinal cancer | Surgery | NOT CLEAR | RCT |
| Effect of route of delivery and formulation of postoperative nutritional support in patients undergoing major operations for malignant neoplasms | Gianotti, L | 1997 | Italy | 86 | 87 | S | Not given | Standard enteral nutrition (preoperative) | Total parenteral nutrition\ (preoperative) | | Gastrointes tinal cancer | Surgery | NO | RCT |
| Perioperative nutrition in malnourished surgical cancer patients e-A prospective, randomized, controlled clinical trial | Klek, S | 2011 | Poland | 43 | 41 | 1 | Malnourish ed | Standard enteral nutrition (preoperative) | Standard parenteral nutrition (preoperative) | | Gastrointes tinal tumors | Surgery | NO | RCT |
| Quick recovery of serum diamine oxidase activity in patients undergoing total gastrectomy by oral enteral nutrition | Kamei, H | 2005 | Japan | 27 | 21 | | Not given | Standard enteral nutrition(posto perative) | Total parenteral nutrition (postoperative) | | Gastric Cancer | Surgery | NO | RCT |

Table 1. Basic characteristics of the studies included in the meta-analysis


Publication Country No of cases Nutrition Intervention Location of Treatment ONS RCT Title Authors EN vear PN CI* status EN PN CI* cancer The comparison between early Kim. HU Total NO RCT 2012 Korea 17 16 Not given Early enteral Gastric Surgery enteral nutrition and total nutrition parenteral Cancer parenteral nutrition after total (preoperative+post nutrition gastrectomy in patients with operative) (preoperative+ gastric cancer the postoperative) randomized prospective study The impact of Klek. S 2008 Poland 53 49 Standard enteral Standard Gastrointesti Surgery NO RCT Not given immunostimulating nutrition nutrition parenteral nal cancer on infectious complications nutrition (postoperative) after upper gastrointestinal (postoperative) surgery: a prospective, randomized, clinical trial China 43 A randomized control study of Wang, D 2014 45 Not given Early oral enteral Fasting Colorectal Surgery YES RCT early oral enteral nutrition (preoperative+ cancer nutrition after colorectal cancer (preoperative+post postoperative) operation operative) Effect of early oral enteral Wang, Z 2013 China 24 24 Excessive Early oral enteral Colorectal YES RCT Conventional Surgery nutrition on clinical obesity or nutrition postoperative cancer outcomes after colorectal malnourished (postoperative) care cancer surgery Effect of early oral enteral Mi, L 2012 China 30 30 Excessive Early oral enteral Conventional Gastric Surgery YES RCT nutrition on clinical nutrition obesity or postoperative Cancer outcomes after gastric malnourished (postoperative) care cancer surgery A randomized controlled trial Wu, GH 2007 215 215 216 malnourished Standard enteral Standard Conventional Gastrointesti Surgery NO RCT China of postoperative artificial postoperative nal cancer nutrition parenteral nutrition in malnourished care (postoperative) nutrition patients with gastrointestinal (postoperative) cancer Chen. W 2014 Early enteral nutrition after 37 Early enteral China 35 Not given Total Gastric Surgery NO No total gastrectomy for gastric nutrition parenteral Cancer cancer (postoperative) nutrition (postoperative)

Table 1. Basic characteristics of the studies included in the meta-analysis (cont.)

| Title | Authors | Publication | Country | No c | of case | | Nutrition | Intervention | | | Location | of Treatment | ONS | RCT |
|--|---------------|-------------|-------------------|------|---------|-----|-----------|---|--|---------------------------------------|-------------------|-----------------|--------------|-----|
| Title | | year | - | EN | PN | CI* | status | EN | PN | CI* | cancer | meatiment | ONS | |
| Impact of early enteral and parenteral nutrition on prealbumin and high- sensitivity C-reactive protein after gastric surgery | Li, B | 2015 | China | 34 | 34 | | Not given | Early enteral nutrition (postoperative) | Standard parenteral nutrition (postoperative) | 2 | Gastric Cancer | Surgery | NO | RCT |
| Nutrition support in surgical patients with colorectal cancer | Chen, Y | 2011 | China | 25 | | 174 | Not given | Standard enteral nutrition (postoperative) | | Conventional postoperative care | | Surgery | NOT CLEAR | No |
| The impact of high protein nutritional support on clinical outcomes and treatment costs of patients with colorectal cancer | Manasek, V | 2016 | Czech Republic | 52 | | 105 | Not given | Oral enteral nutrition (preoperative+po stoperative) | | Conventional care | Colorectal cancer | Surgery | YES | No |
| The postoperative clinical outcomes and safety of early enteral nutrition in operated gastric cancer patients | Li, B | 2015 | China | 200 | 200 | | Not given | Early enteral nutrition (postoperative) | Standard parenteral nutrition (postoperative) | | Gastric Cancer | Surgery | NO | RCT |
| Clinical effects of early enteral nutrition in patients after laparoscopic surgery for colorectal cancer | Niu, WB | 2015 | China | 54 | 54 | R | Not given | Early enteral nutrition (postoperative) | Standard parenteral nutrition (postoperative) | | Colorectal cancer | Surgery | NO | RCT |
| Effect of early enteral nutrition on postoperative recovery in patients with colon cancer | Yixun, Z | 2014 | China | 30 | | 30 | Not given | Early enteral nutrition (postoperative) | | Conventional postoperative care | | Surgery | NO | RCT |
| Effect of postoperative early enteral nutrition on the recovery of humoral immune function in patients with colorectal carcinoma undergoing elective resection | Yang, D | 2013 | China | 32 | | 39 | Not given | Early oral enteral nutrition (postoperative) | | Conventional postoperative care | | Surgery | Yes | RCT |
| Impact of enteral nutrition or parenteral nutrition in post- operative colorectal cancer patients on viscera organ functions and "passing wind" time | Yu, HZ | 2009 | China | 15 | 15 | | Not given | Standard enteral nutrition (postoperative) | Standard parenteral nutrition (postoperative) | | Colorectal cancer | Surgery | No | RCT |

Table 1. Basic characteristics of the studies included in the meta-analysis (cont.)





| Study | Total | Enteral n Mean | utrition SD | Pare Total | nteral nu Mean | itrition SD | Mean Difference | MD | 95%-CI | Weight (fixed) | Weight (random) |
|--|----------------|------------------------|----------------------|----------------|-------------------------|---------------------|--------------------|-------------------------|---|-----------------------|-------------------------|
| Wang, J(2018) Kamei, H(2005) Chen, W(2014) | 66 27 37 | 24000 9866 36472 | 19000 422 4833 | 63 21 35 | 33000 11313 40410 | 8000 645 3927 | | -9000 -1447 -3938 | [-13991; -4009] [-1766; -1129] [-5967; -1909] | 0.4% 97.2% 2.4% | 20.4% 43.1% 36.5% |
| Fixed effect model Random effects model Heterogeneity: $I^2 = 86\%$, τ^2 | | 14.4288, <i>p</i> | < 0.01 | 119 | | | -10000 0 500010000 | -1537 -3898 | [-1851;-1223] [-6999;-796] | 100.0% | 100.0% |

Figure 2. Meta-analysis comparing hospitalization expenditure between the EN and PN groups.

| | | Enteral r | nutrition | Conve | ntional inte | rvention | | | | Weight | Weight |
|--|-------------|---------------|-----------|-------|--------------|----------|-----------------|-------|----------------|---------|----------|
| Study | Total | Mean | SD | Total | Mean | SD | Mean Difference | MD | 95%-CI | (fixed) | (random) |
| Wang, D(2014) | 43 | 41868 | 3168 | 45 | 45950 | 3714 | - | -4082 | [-5522; -2642] | 46.2% | 30.1% |
| Wang, Z(2013) | 24 | 36300 | 6400 | 24 | 42800 | 4300 | | -6500 | [-9585; -3415] | 10.1% | 21.5% |
| Mi, L(2012) | 30 | 30220 | 3220 | 30 | 34600 | 3210 | | -4380 | [-6007; -2753] | 36.2% | 29.2% |
| Chen, Y(2011) | 25 | 44210 | 7635 | 174 | 42060 | 13066 | | 2150 | [-1417; 5717] | 7.5% | 19.2% |
| Fixed effect model | 122 | | | 273 | | | ۵ | -3964 | [-4943; -2985] | 100.0% | |
| Random effects model Heterogeneity: $I^2 = 79\%$, τ^2 | = 4350532.6 | 181. p < 0.01 | | | | | | -3494 | [-5871; -1117] | | 100.0% |
| i e e e general, i e e e, e | | , p | | | | | -5000 0 5000 | | | | |
| | | | | | | | | | | | |

Figure 3. Meta-analysis comparing hospitalization expenditure between the EN and CI groups.

| | En | teral nu | trition | Paren | teral nut | trition | | | | Weight | Weight |
|--|-----------------------|-------------|---------|-------|-----------|---------|-----------------|-------|-----------------|---------|----------|
| Study | Total | Mean | SD | Total | Mean | SD | Mean Difference | MD | 95%-CI | (fixed) | (random) |
| Wang, J(2018) | 66 | 12.30 | 4.50 | 63 | 18.10 | 3.70 | į | -5.80 | [-7.22; -4.38] | 4.6% | 10.9% |
| Gianotti, L(1997) | 87 | 19.20 | 7.90 | 86 | 21.60 | 8.90 | | -2.40 | [-4.91; 0.11] | 1.5% | 6.9% |
| Kamei, H(2005) | 51 | 23.10 | 7.20 | 78 | 27.60 | 4.70 | | -4.50 | [-6.73; -2.27] | 1.8% | 7.7% |
| Klek, S(2008) | 53 | 12.40 | 3.90 | 49 | 12.90 | 4.90 | | -0.50 | [-2.23; 1.23] | 3.1% | 9.6% |
| Wu, G H(2007) | 215 | 9.80 | 3.40 | 215 | 11.20 | 5.00 | | -1.40 | [-2.21; -0.59] | 14.1% | 13.4% |
| Chen, W(2014) | 37 | 12.20 | 2.50 | 35 | 14.90 | 2.90 | <u>-</u> # | -2.70 | [-3.95; -1.45] | 5.9% | 11.6% |
| Li, B(2015) | 34 | 16.20 | 3.60 | 34 | 19.70 | 4.50 | | -3.50 | [-5.44; -1.56] | 2.5% | 8.8% |
| Niu, W B(2015) | 54 | 13.10 | 1.25 | 54 | 16.80 | 2.41 | = | -3.70 | [-4.42;-2.98] | 17.6% | 13.7% |
| Yu, H Z(2009) | 15 | 13.20 | 5.40 | 15 | 20.40 | 7.10 | | -7.20 | [-11.71; -2.69] | 0.5% | 3.1% |
| Li, B(2016) | 200 | 6.80 | 1.90 | 200 | 9.30 | 2.50 | | -2.50 | [-2.94; -2.06] | 48.6% | 14.5% |
| Fixed effect model | 812 | | | 829 | | | 0 | -2.74 | [-3.04; -2.43] | 100.0% | |
| Random effects model | | | | | | | <u> </u> | -3.09 | [-3.98; -2.20] | | 100.0% |
| Heterogeneity: $I^2 = 82\%$, τ^2 | ² = 1.3798 | 8, p < 0.01 | 1 | | | | | | | | |
| | | | | | | | -10 -5 0 5 10 | | | | |

Figure 4. Meta-analysis comparing LOH between the EN and PN groups.

| Figure 4. Micta-allar | ysis coi | nparing | LOIL | between | | illu r IN | groups. | | | | |
|--|---|---|--|--|---|--|-----------------|--|--|--|---|
| Study | Total | Enteral n Mean | utrition SD | Convent Total | ional interv Mean | vention SD | Mean Difference | MD | 95%-CI | Weight (fixed) | Weight (random) |
| ONS Gianotti, L(2002) Wang, D(2014) Wang, Z(2013) Mi, L(2012) Manasek, V(2016) Yang, D(2013) Fixed effect model Random effects model Heterogeneity: $I^2 = 86\%, \tau^2 =$ | 102 43 24 30 52 32 283 | 11.60 6.90 5.40 7.83 9.40 6.00 | 4.70 1.40 1.10 2.23 5.00 1.00 | 102 45 24 30 105 39 345 | 14.00 8.50 7.10 9.57 12.00 11.70 | 7.70 1.90 1.40 1.96 6.40 3.80 | * | -2.40 -1.60 -1.70 -1.74 -2.60 -5.70 -2.17 -2.57 | [-4.15; -0.65] [-2.30; -0.90] [-2.41; -0.99] [-2.80; -0.68] [-4.43; -0.77] [-6.94; -4.46] [-2.57; -1.77] [-3.75; -1.40] | 4.0% 25.4% 24.2% 10.9% 3.7% 8.0% 76.2% | 9.3% 13.0% 13.0% 11.8% 9.1% 11.2% 67.4% |
| Other EN feeding method Gunerhan, Y(2009) Wu, G H(2007) Chen, Y(2011) Yixun, Z(2014) Fixed effect model Random effects model Heterogeneity: $I^2 = 78\%, \tau^2 =$ Fixed effect model Random effects model Heterogeneity: $I^2 = 82\%, \tau^2 =$ | 13 215 25 30 283 : 2.9555, p 566 | | 9.12 3.40 4.34 1.57 | 13 59 174 30 276 621 | 12.00 14.50 15.77 11.80 | 3.69 7.10 6.03 1.83 | | 2.22 -4.70 -3.85 -1.69 -2.37 -2.72 -2.22 -2.64 | [-3.13; 7.57] [-6.57; -2.83] [-5.77; -1.93] [-2.55; -0.83] [-3.09; -1.65] [-4.75; -0.68] [-2.57; -1.87] [-3.57; -1.72] | 0.4% 3.5% 3.3% 16.5% 23.8% 100.0% | 2.5% 8.9% 8.7% 12.5% |

Figure 5. Meta-analysis comparing the LOH between the EN and CI groups.

| Study | Events | Total | | Proportion | 95%-CI | Weight (fixed) | Weight (random) |
|---|---|--|---------------|--|--|---|---|
| ONS Gianotti, L(2002) Wang, D(2014) Wang, Z(2013) Mi, L(2012) Fixed effect model Random effects model Heterogeneity: $I^2 = 5\%$, $\tau^2 = 0.0$ | 14 2 2 1166, <i>p</i> = 0.37 | 102 43 24 30 199 | | 0.14 0.05 0.08 0.07 0.11 0.11 | [0.08; 0.22] [0.01; 0.16] [0.01; 0.27] [0.01; 0.22] [0.07; 0.16] [0.07; 0.16] | 15.8% 3.0% 2.8% 2.9% 24.5% | 9.8% 6.5% 6.4% 6.4% 29.1% |
| Other EN feeding methods Wang, J(2018) Gunerhan, Y(2009) Gianotti, L(1997) Klek, S(2011) Kamei, H(2005) Kim, H U(2012) Klek, S(2008) Wu, G H(2007) Chen, W(2014) Niu, W B(2015) Fixed effect model Random effects model Heterogeneity: $J^2 = 82\%$, $\tau^2 = 0$. | 0 8 7 13 2 0 15 22 3 2 8487, p < 0.01 | 66 13 87 43 27 17 53 215 37 54 612 | | 0.00 0.62 0.08 0.30 0.07 0.00 0.28 0.10 0.08 0.04 0.16 0.13 | [0.00; 0.05] [0.32; 0.86] [0.03; 0.16] [0.17; 0.46] [0.01; 0.24] [0.00; 0.20] [0.17; 0.42] [0.07; 0.15] [0.02; 0.22] [0.00; 0.13] [0.13; 0.19] [0.07; 0.23] | 0.6% 4.2% 8.7% 11.9% 2.9% 0.6% 14.0% 3.0% 75.5% | 2.6% 7.4% 9.4% 6.4% 2.5% 9.6% 10.2% 7.3% 6.5% |
| Fixed effect model Random effects model Heterogeneity: $I^2 = 76\%$, $\tau^2 = 0$. | 6058, p < 0.01 | 811 | 0 0.2 0.4 0.6 | 0.15 0.12 | [0.12; 0.18] [0.08; 0.19] | 100.0% | 100.0% |
| Figure 6. Meta-analysis of | of the infecti | ion rate | with EN. | e X | | | |
| | | | | | | Weight | Weight |

| Study | Events | Total | | Proportion | 95%-CI | Weight (fixed) | Weight (random) |
|--|----------------|-------|-----------------------|------------|--------------|-------------------|--------------------|
| Wang, J(2018) | 29 | 63 | | 0.46 | [0.33; 0.59] | 20.4% | 14.5% |
| Gianotti, L(1997) | 10 | 86 | | 0.12 | [0.06; 0.20] | 11.9% | 13.6% |
| Klek, S(2011) | 10 | 41 | | 0.24 | [0.12; 0.40] | 10.1% | 13.3% |
| Kamei, H(2005) | 1 | 21 | | 0.05 | 0.00; 0.24] | 1.8% | 7.5% |
| Kim, H U(2012) | 0 | 16 | · | 0.00 | [0.00; 0.21] | 0.6% | 3.7% |
| Klek, S(2008) | 13 | 49 | | 0.27 | [0.15; 0.41] | 12.7% | 13.8% |
| Wu, G H(2007) | 33 | 215 | | 0.15 | 0.11; 0.21] | 36.4% | 15.1% |
| Chen, W(2014) | 1 | 35 | | 0.03 | 0.00; 0.15 | 1.8% | 7.6% |
| Niu, W B(2015) | 3 | 54 | | 0.06 | [0.01; 0.15] | 4.2% | 10.8% |
| Fixed effect model | | 580 | \diamond | 0.20 | [0.17; 0.24] | 100.0% | |
| Random effects model Heterogeneity: $I^2 = 83\%$, $\tau^2 = 0$ |) 6210 p < 0.0 | 1 | | 0.16 | [0.09; 0.26] | | 100.0% |
| Helelogeneily. 7 – 65%, t – 0 | p < 0.0 | | 0 0.1 0.2 0.3 0.4 0.5 | | | | |

Figure 7. Meta-analysis of infection rate with PN.

| Study | Events | Total | | Proportion | 95%-CI | Weight (fixed) | Weight (random) |
|--|-------------------|-------|-------------------------|------------|--------------|-------------------|--------------------|
| Gianotti, L(2002) | 31 | 102 | | 0.30 | [0.22; 0.40] | 29.0% | 26.4% |
| Gunerhan, Y(2009) | 4 | 13 | | 0.31 | 0.09: 0.61 | 3.7% | 12.4% |
| Wang, D(2014) | 4 | 45 | | 0.09 | [0.02: 0.21] | 4.9% | 14.5% |
| Wang, Z(2013) | 1 | 24 | | 0.04 | [0.00: 0.21] | 1.3% | 5.8% |
| Mi, L(2012) | 3 | 30 | | 0.10 | 0.02: 0.27 | 3.6% | 12.2% |
| Wu, G H(2007) | 59 | 216 | | 0.27 | [0.21; 0.34] | 57.5% | 28.7% |
| Fixed effect model | | 430 | | 0.26 | [0.22; 0.30] | 100.0% | |
| Random effects model Heterogeneity: $I^2 = 67\%$, τ^2 | = 0.2332, p = 0.0 | 1 | | 0.20 | [0.13; 0.30] | - | 100.0% |
| , ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, | | | 0.1 0.2 0.3 0.4 0.5 0.6 | | | | |

Figure 8. Meta-analysis of the infection rate with CI.